Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Uncategorized

Monness, Crespi, Hardt Downgrades At Home Group to Neutral

Monness, Crespi, Hardt analyst Jim Chartier downgrades At Home Group (NYSE:HOME) from Buy to Neutral.

byBenzinga Newsdesk

May 10, 2021

1 minute read

Monness, Crespi, Hardt analyst Jim Chartier downgrades At Home Group (NYSE:HOME) from Buy to Neutral.

Analyst Ratings

4 Analysts Have This to Say About Magnolia Oil & Gas

By Benzinga Insights

Today, 5:37 AM

Within the last quarter, Magnolia Oil & Gas (NYSE:MGY) has observed the following analyst ratings:

MGY

Square Shares Up ~1% After Hours; Hearing Co. Founder Jack Dorsey Has Won Patent For Fiat-To-Crypto Payments Network; However, Article From 7-8 Hours Ago

By Benzinga Newsdesk

Today, 5:37 AM

https://hedgemaven.maven-data.com/news/crypto/jack-dorseys-square-wins-patent-for-fiat-to-crypto-payments-network

Needham Sees Netflix’s Ad Driven Tier Dependent On Measurement; Looks Forward To CTV Measurement Conference Next Week

By Anusuya Lahiri

Today, 5:37 AM

Needham analyst Laura Martin continues to consider it vital for Netflix, Inc (NASDAQ:NFLX) to launch its ad-driven streaming tier, add Sports…

CTV

Thinking About Buying Stock Or Options In Tilray, Ocugen, Biogen Or Snowflake?

By Henry Khederian

Today, 5:37 AM

One of the most common questions traders have about stocks is “Why Is It Moving?” That’s why Benzinga created the Why Is It Moving, or WIIM, feature in Benzinga Pro. WIIMs are a one-sentence description as to why that stock is moving.

BIIB

Monness, Crespi, Hardt Downgrades At Home Group to Neutral

Related Posts

4 Analysts Have This to Say About Magnolia Oil & Gas

Square Shares Up ~1% After Hours; Hearing Co. Founder Jack Dorsey Has Won Patent For Fiat-To-Crypto Payments Network; However, Article From 7-8 Hours Ago

Needham Sees Netflix’s Ad Driven Tier Dependent On Measurement; Looks Forward To CTV Measurement Conference Next Week

Thinking About Buying Stock Or Options In Tilray, Ocugen, Biogen Or Snowflake?